Clinical Trial

Effects and Safety of Clonidine Patch on Young and Middle-aged Smokers With Mild Hypertension

Study acronym: ECLIPSE
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The optimal antihypertensive treatment strategy in young and middle-aged hypertensive adults remains undefined. Clonidine controlled-release patches administered once a week might have the advantage of convenience. ECLIPSE trial is intended to explore the effect and patient tolerability of clonidine controlled-release patches (one patch per week for a total of 8 weeks) in the treatment of hypertension in young and middle-aged adults, compared with long-acting antihypertensive drug amlodipine. Clonidine patch was demonstrated ameliorating the early withdrawal symptoms during smoking cessation. This trial is also intended to observe its effect on smoking cessation in young and middle-aged male smokers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-06-09; most recent amendment 2024-01-14.
Trial Details
NCT Number NCT05416840
Lead Sponsor Jing Liu
Conditions Hypertension
Enrollment 92 participants
Start Date 2024-01
Primary Completion 2026-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-01-17